Immediate Impact

1 from Science/Nature 67 standout
Sub-graph 1 of 22

Citing Papers

Borderline Personality Disorder
2023 Standout
Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline–trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial
2023 Standout
5 intermediate papers

Works of J. Reilly being referenced

The Clinical Effectiveness and Cost-Effectiveness of Lamotrigine in Borderline Personality Disorder: A Randomized Placebo-Controlled Trial
2018
Efficacy and Safety of MIN-101: A 12-Week Randomized, Double-Blind, Placebo-Controlled Trial of a New Drug in Development for the Treatment of Negative Symptoms in Schizophrenia
2017
and 2 more

Author Peers

Author Last Decade Papers Cites
J. Reilly 203 151 28 72 22 488
Mikkel Højlund 264 138 41 33 42 530
Brian J. Cohen 142 45 14 113 26 569
Aniyizhai Annamalai 187 65 17 37 20 448
Joel J. Silverman 155 132 26 31 34 491
Dieter Schoepf 208 142 15 26 22 555
A. Weeke 277 198 38 15 19 567
Adityanjee 216 101 31 27 28 434
Christianna Purnell 231 62 29 31 17 573
Mary E. Swigar 216 113 29 22 30 468
F Casadebaig 358 121 23 18 21 487

All Works

Loading papers...

Rankless by CCL
2026